Abstract
It is a current idea that carcinogenesis as well as tumor progression are dynamic processes, which involve inherited as well as somatic mutations and include a continuing adaptation to different microenvironmental conditions. There is, in fact, rising evidence that tumor cells are under a persistent stress and that autocrine as well as microenvironment- derived survival factors play a substantial role for the final outcome of the tumor development as well as for response to the anti-tumor therapy. We will review current achievements on the molecular biology of the microenvironment- derived survival signaling and therapeutical approaches, which are presently under clinical development. By the use of plasma cell disorders as an outstanding clinical model, we will discuss the development of novel in vivo preclinical models which recapitulate the human bone marrow milieu. Finally, we will discuss several topics which appear to be relevant for a successful clinical translation of preclinical research in this specific field.
Keywords: Tumor microenvironment, survival pathways, in vivo animal models, in vivo preclinical models, SCID-hu, multiple myeloma, Waldenstrom's macroglobulinemia
Current Pharmaceutical Design
Title: Novel Therapeutic Approaches Based on the Targeting of Microenvironment-Derived Survival Pathways in Human Cancer: Experimental Models and Translational Issues
Volume: 13 Issue: 5
Author(s): Pierfrancesco Tassone, Pierosandro Tagliaferri, Maria Teresa Fulciniti, Maria Teresa Di Martino and Salvatore Venuta
Affiliation:
Keywords: Tumor microenvironment, survival pathways, in vivo animal models, in vivo preclinical models, SCID-hu, multiple myeloma, Waldenstrom's macroglobulinemia
Abstract: It is a current idea that carcinogenesis as well as tumor progression are dynamic processes, which involve inherited as well as somatic mutations and include a continuing adaptation to different microenvironmental conditions. There is, in fact, rising evidence that tumor cells are under a persistent stress and that autocrine as well as microenvironment- derived survival factors play a substantial role for the final outcome of the tumor development as well as for response to the anti-tumor therapy. We will review current achievements on the molecular biology of the microenvironment- derived survival signaling and therapeutical approaches, which are presently under clinical development. By the use of plasma cell disorders as an outstanding clinical model, we will discuss the development of novel in vivo preclinical models which recapitulate the human bone marrow milieu. Finally, we will discuss several topics which appear to be relevant for a successful clinical translation of preclinical research in this specific field.
Export Options
About this article
Cite this article as:
Tassone Pierfrancesco, Tagliaferri Pierosandro, Teresa Fulciniti Maria, Teresa Di Martino Maria and Venuta Salvatore, Novel Therapeutic Approaches Based on the Targeting of Microenvironment-Derived Survival Pathways in Human Cancer: Experimental Models and Translational Issues, Current Pharmaceutical Design 2007; 13 (5) . https://dx.doi.org/10.2174/138161207780162872
DOI https://dx.doi.org/10.2174/138161207780162872 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Adenosine Receptors as Novel Targets for the Treatment of Various Cancers
Current Pharmaceutical Design Mouse ATP-Binding Cassette (ABC) Transporters Conferring Multi-Drug Resistance
Anti-Cancer Agents in Medicinal Chemistry A Review of Preclinical Experiments Toward Targeting M2 Macrophages in Prostate Cancer
Current Drug Targets Co-formulation of P-glycoprotein Substrate and Inhibitor in Nanocarriers: An Emerging Strategy for Cancer Chemotherapy
Current Cancer Drug Targets Tumor Necrosis Factor Alpha in Ulcerative Colitis and Diverticular Disease Associated Colitis
Endocrine, Metabolic & Immune Disorders - Drug Targets Combinatorial Nanoparticles for Cancer Diagnosis and Therapy
Current Medicinal Chemistry Tumour Reactions to Hypoxia
Current Molecular Medicine Jumping on the Train of Personalized Medicine: A Primer for Non- Geneticist Clinicians: Part 3. Clinical Applications in the Personalized Medicine Area
Current Psychiatry Reviews Methionine Aminopeptidases as Potential Targets for Treatment of Gastrointestinal Cancers and other Tumors
Current Drug Targets EDITORIAL: Advances in Developing Versatile Tools for the Discovery of Novel Therapeutics
Current Topics in Medicinal Chemistry Cell Cycle and Energy Metabolism in Tumor Cells: Strategies for Drug Therapy
Recent Patents on Anti-Cancer Drug Discovery Resveratrol: A Therapeutic Promise for Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Immune Responses to Gene-Modified T Cells
Current Gene Therapy Biomedical Applications of Superparamagnetic Nanoparticles in Molecular Scale
Current Organic Chemistry Using a Hybrid Radioenhancer to Discover Tumor Cell-targeted Treatment for Osteosarcoma: An In Vitro Study
Current Medicinal Chemistry Plasma VEGF and IL-8 Levels in Patients with Mixed Dyslipidaemia. Effect of Rosuvastatin Monotherapy or its Combination at a Lower Dose with Omega-3 Fatty Acids: A Pilot Study
Current Vascular Pharmacology Potentiation of Anti-Cancer Treatment by Modulators of Energy Metabolism
Current Pharmaceutical Biotechnology Differentiation of iNKT Cells from Embryonic Stem Cells
Current Immunology Reviews (Discontinued) Artesunate Enhances the Antiproliferative Effect of Temozolomide on U87MG and A172 Glioblastoma Cell Lines
Anti-Cancer Agents in Medicinal Chemistry A Potent Inhibitor of Steroid Sulfatase (EM-1913) Blocks Tumor Growth in Nude Mice (MCF-7 Xenograft)
Current Enzyme Inhibition